Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity
Tóm tắt
To evaluate the outcome of intravitreal bevacizumab (IVB) and aflibercept (IVA) injection for patients with retinopathy of prematurity (ROP). In this single-center retrospective cohort, the recorded medical data of the infants who had been undergone intravitreal injection with either bevacizumab or aflibercept for type 1 ROP were reviewed. The infants were allocated into two groups. IVB group included patients who were treated with bevacizumab as initial treatment and the IVA group included patients who were treated with aflibercept as initial treatment. The rate and time of complete regression, as well as the recurrence rates, were compared between the groups. A total of 889 eyes of 453 infants were enrolled in the study. There were 865 eyes of 441 infants in the IVB group and 24 eyes of 12 infants in the IVA group. Follow-up time was 289 ± 257 days in the IVB group and 143 ± 25 days in the IVA group (p < 0.001). The difference in the ROP zone was not statistically significant between the 2 treatment groups (p = 0.328). All eyes in the IVA group showed initial regression of ROP after the intravitreal injections. These regressions were achieved in 830 (96.0%) eyes that were injected with IVB (p = 0.023). The median observed regression time was 10 days and 16 days in eyes treated with bevacizumab and aflibercept respectively. Recurrence was noted in 3.9% of eyes (34/865) in the IVB group and 58.3% of eyes (14/24) in the IVA group (p < 0.001). While the regression rate in the IVA group was significantly higher than in the IVB group, the recurrence rate was significantly more in the IVA group, which may be attributed to differences in the pharmacokinetics of these drugs in the vitreous body.
Tài liệu tham khảo
Kong L, Fry M, Al-Samarraie M, Gilbert C, Steinkuller PG. An update on progress and the changing epidemiology of causes of childhood blindness worldwide. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2012;16:501–7.
Roohipoor R, Karkhaneh R, Riazi-Esfahani M, Farahani AD, Khodabandeh A, Adib NE, et al. Comparison of intravitreal bevacizumab and laser photocoagulation in the treatment of retinopathy of prematurity. Ophthalmol Retin Elsevier. 2018;2:942–8.
Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. N Engl J Med. 2012;367:2515–26.
Hartnett ME. Pathophysiology and mechanisms of severe retinopathy of prematurity. Ophthalmology. 2015;122:200–10.
Axer-Siegel R, Maharshak I, Snir M, Friling R, Ehrlich R, Sherf I, et al. Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes. Retina. 2008;28:839–46.
Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364:603–15.
Yetik H, Gunay M, Sirop S, Salihoglu Z. Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. Graefe’s Arch Clin Exp Ophthalmol. 2015;253:1677–83.
Mueller B, Salchow DJ, Waffenschmidt E, Joussen AM, Schmalisch G, Czernik C, et al. Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone. Br J Ophthalmol England. 2017;101:365–70.
Sukgen EA, Koçluk Y. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:49–55.
Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15:171–85.
Vural A, Yıldız ED. Comparison of Vascular Outgrowth Rate and Retinal Vascular Development Border after Intravitreal Injection of Aflibercept or Bevacizumab to Treat Retinopathy of Prematurity. Ophthalmol J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkd. 2020;243:86–93.
Bazvand F, Riazi-Esfahani H, Mirshahi A, Khodabande A, Khojastheh H, Farahani AD, et al. Ocular complications following intravitreal bevacizumab injection for retinopathy of prematurity and assessment of risk factors. Int J Retin Vitr BioMed Central. 2021;7:1–8.
Alyamaç Sukgen E, Çömez A, Koçluk Y, Cevher S. The Process of Retinal Vascularization after Anti-VEGF Treatment in Retinopathy of Prematurity: A Comparison Study between Ranibizumab and Bevacizumab. Ophthalmol J Int d’ophtalmologie Int J Ophthalmol Zeitschrift fur Augenheilkd. 2016;236:139–47.
Martínez-Castellanos MA, Schwartz S, Hernández-Rojas ML, Kon-Jara VA, García-Aguirre G, Guerrero-Naranjo JL, et al. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up. Retina. 2013;33:329–38.
Zhang G, Yang M, Zeng J, Vakros G, Su K, Chen M, et al. Comparison of intravitreal injection of ranibizumab versus laser therapy for zone ii treatment-requiring retinopathy of prematurity. Retina. 2017;37:710–7.
Salman AG, Said AM. Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity. Ophthalmic Res. 2015;53:15–20.
Huang C-Y, Lien R, Wang N-K, Chao A-N, Chen K-J, Chen T-L, et al. Changes in systemic vascular endothelial growth factor levels after intravitreal injection of aflibercept in infants with retinopathy of prematurity. Graefe’s Arch Clin Exp Ophthalmol. 2018;256:479–87.
Vedantham V. Intravitreal aflibercept injection in Indian eyes with retinopathy of prematurity. Indian J Ophthalmol. 2019;67:884–8.
Moisseiev E, Waisbourd M, Ben-Artsi E, Levinger E, Barak A, Daniels T, et al. Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes. Graefe’s Arch Clin Exp Ophthalmol. 2014;252:331–7.
Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32:434–57.
Hartnett ME. Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity. Clin Perinatol. 2014;41:925–43.
Kim J, Kim SJ, Chang YS, Park WS. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity. Retina. 2014;34:77–82.
Ekinci DY, Vural AD. Comparison of two different doses of intravitreal aflibercept in the treatment of retinopathy of prematurity. J AAPOS Off Publ Am Assoc Pediatr Ophthalmol Strabismus. 2021;25:93–93.